Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Major Shareholder Sells $42,018.48 in Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) major shareholder Pharmaceutical Co Ltd Takeda sold 1,191 shares of the firm’s stock in a transaction on Wednesday, June 9th. The stock was sold at an average price of $35.28, for a total transaction of $42,018.48. Following the transaction, the insider now directly owns 940,814 shares in the company, valued at $33,191,917.92. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Pharmaceutical Co Ltd Takeda also recently made the following trade(s):

  • On Monday, June 7th, Pharmaceutical Co Ltd Takeda sold 2,264 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.05, for a total transaction of $79,353.20.
  • On Tuesday, June 1st, Pharmaceutical Co Ltd Takeda sold 11,211 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $35.78, for a total transaction of $401,129.58.
  • On Friday, May 28th, Pharmaceutical Co Ltd Takeda sold 8,905 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $36.19, for a total transaction of $322,271.95.
  • On Wednesday, May 26th, Pharmaceutical Co Ltd Takeda sold 12,358 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $36.64, for a total transaction of $452,797.12.
  • On Wednesday, May 26th, Pharmaceutical Co Ltd Takeda sold 12,358 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $36.64, for a total transaction of $452,797.12.
  • On Monday, May 24th, Pharmaceutical Co Ltd Takeda sold 10,594 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.66, for a total transaction of $377,782.04.
  • On Thursday, May 20th, Pharmaceutical Co Ltd Takeda sold 7,098 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.10, for a total transaction of $249,139.80.
  • On Friday, May 14th, Pharmaceutical Co Ltd Takeda sold 100 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.00, for a total transaction of $3,500.00.
  • On Wednesday, May 12th, Pharmaceutical Co Ltd Takeda sold 11,776 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.44, for a total transaction of $417,341.44.
  • On Friday, May 7th, Pharmaceutical Co Ltd Takeda sold 1,011 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.03, for a total transaction of $35,415.33.

NASDAQ:PHAT opened at $34.92 on Friday. The firm has a 50 day moving average price of $36.16. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -8.31 and a beta of 1.14. Phathom Pharmaceuticals, Inc. has a 1-year low of $28.10 and a 1-year high of $51.70.

Phathom Pharmaceuticals (NASDAQ:PHAT) last posted its quarterly earnings data on Tuesday, May 11th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.15. Equities analysts expect that Phathom Pharmaceuticals, Inc. will post -3.65 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of PHAT. Gilder Gagnon Howe & Co. LLC acquired a new position in Phathom Pharmaceuticals during the first quarter worth approximately $30,739,000. Janus Henderson Group PLC increased its position in Phathom Pharmaceuticals by 23.6% during the fourth quarter. Janus Henderson Group PLC now owns 1,938,436 shares of the company’s stock worth $64,396,000 after purchasing an additional 369,640 shares during the last quarter. Norges Bank acquired a new position in Phathom Pharmaceuticals during the fourth quarter worth approximately $10,941,000. Jefferies Group LLC acquired a new position in Phathom Pharmaceuticals during the fourth quarter worth approximately $8,224,000. Finally, GW&K Investment Management LLC acquired a new position in Phathom Pharmaceuticals during the first quarter worth approximately $7,494,000. 77.06% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 3rd. The Goldman Sachs Group upgraded shares of Phathom Pharmaceuticals from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $40.00 to $48.00 in a research report on Wednesday, May 12th. Finally, BMO Capital Markets assumed coverage on shares of Phathom Pharmaceuticals in a research report on Wednesday, February 17th. They set an “outperform” rating and a $63.00 target price for the company. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Phathom Pharmaceuticals has a consensus rating of “Buy” and an average price target of $53.00.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

See Also: What does an inverted yield curve signify?

Insider Buying and Selling by Quarter for Phathom Pharmaceuticals (NASDAQ:PHAT)

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.